13/05/2026
There has recently been an important change in how we understand and describe PCOS.
As of May 2026, Polycystic O***y Syndrome (PCOS) has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This update was published in The Lancet following a global consensus from researchers, healthcare professionals, and patient advocates.
The name change is more than just wording — it reflects a growing understanding that this condition affects the whole body, not just the ovaries.
Why was the name changed?
For many years, the term “polycystic o***y syndrome” caused confusion and misunderstanding.
- The word “polycystic” is technically inaccurate, as the ovaries usually contain follicles rather than true cysts.
- Many people with PCOS do not actually have visible ovarian cysts on ultrasound.
- The old name often led people to believe it was purely a fertility or reproductive issue.
In reality, PMOS can affect many areas of health, including:
- Hormones and menstrual cycles
- Insulin resistance and blood sugar control
- Weight and metabolism
- Skin and hair changes
- Energy levels and inflammation
- Mental health and emotional wellbeing
- Fertility and reproductive health
Why does this matter?
The updated name helps validate what many women have experienced for years — that this condition is complex, real, and impacts far more than just periods or ovaries.
It is also hoped that the change will:
- Improve awareness and earlier diagnosis
- Reduce stigma and misunderstanding
- Encourage more whole-body treatment approaches
- Help women feel more seen, heard, and supported
PMOS is estimated to affect around 1 in 8 women globally, yet many remain undiagnosed or misunderstood for years.
While the name has changed, the goal remains the same: helping women better understand their bodies, improve their symptoms, and receive compassionate, evidence-based care.
